Tonix Pharmaceuticals (TNXP) director buys 1,000 company shares
Rhea-AI Filing Summary
Tonix Pharmaceuticals Holding Corp. (TNXP) director Richard H. Bagger reported purchasing 1,000 shares of the company’s common stock on August 20, 2026. The shares were bought at a price of $12.60 per share, and he now holds 1,000 shares of Tonix common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 1,000 shares
Net Buy
1 txn
Insider
BAGGER RICHARD H
Role
Director
Bought
1,000 shs ($13K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock, par value $0.001 | 1,000 | $12.60 | $13K |
Holdings After Transaction:
Common Stock, par value $0.001 — 1,000 shares (Direct)
Key Figures
Shares purchased: 1,000 shares
Purchase price per share: $12.60 per share
Shares owned after transaction: 1,000 shares
+1 more
4 metrics
Shares purchased
1,000 shares
Common Stock, par value $0.001; transaction on August 20, 2026
Purchase price per share
$12.60 per share
Price for non-derivative purchase on August 20, 2026
Shares owned after transaction
1,000 shares
Total Tonix common shares directly owned following reported purchase
Net shares bought
1,000 shares
Net-buy direction from transaction summary for this Form 4
Key Terms
Form 4, Common Stock, par value $0.001, non-derivative
3 terms
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Common Stock, par value $0.001 financial
"security_title": "Common Stock, par value $0.001""
non-derivative financial
"transaction_type": "non-derivative""
FAQ
What insider transaction did TNXP director Richard H. Bagger report?
He reported a purchase of 1,000 shares of Tonix Pharmaceuticals Holding Corp. common stock on August 20, 2026, at a price of $12.60 per share, and now directly holds 1,000 shares.
Was the TNXP Form 4 transaction a purchase or a sale?
The Form 4 reports a purchase of Tonix Pharmaceuticals Holding Corp. common stock, coded as a P transaction, indicating an open market or private transaction buy.
Is the reported TNXP insider transaction classified as derivative or non-derivative?
The transaction is classified as non-derivative, involving common stock of Tonix Pharmaceuticals Holding Corp. rather than options or other derivative securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
